Article
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.
The Journal of clinical investigation - 1 Feb 2001
Ono S K, Kato N, Shiratori Y, Kato J, Goto T, Schinazi R F, Carrilho F J, Omata M
Abstract excerpt
After receiving lamivudine for 3 years to treat chronic hepatitis B, 67-75% of patients develop B-domain L528M, C-domain M552I, or M552V mutations in the HBV polymerase that render hepatitis B virus (HBV) drug-resistant. The aim of this study was to evaluate the influence of these mutations on viral replication and resistance to antiviral agents. We investigated the replication fitness and susceptibility of the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
